The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises Flywheel Dynamix on $7 Million Seed Round
On November 20, 2024, Flywheel Dynamix (Flywl), a buyer-centric cloud marketplace designed to simplify software acquisition for buyers and help sellers grow revenue faster, announced a successful raise of $7 million in Seed funding. Storm Ventures, Foster Ventures, BeeNex, FeBe, and Teknos Ventures led the round. After operating in stealth mode since August 2024, Flywl will officially launch the first buyer module for its marketplace platform in the first week of December 2024. With its new capital, Flywl will accelerate the product development of its Meta Marketplace Platform, expand its R&D team, and roll out the platform to initial customers.
Client Highlights
Wilson Sonsini Secures Complete Trial Victory for RWE
On November 19, 2024, firm client RWE achieved a complete trial victory following years of hard-fought litigation, culminating in a five-day bench trial in the U.S. District Court for the Southern District of New York.
Client Highlights
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
On November 18, 2024, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), announced that it has closed a $24 million Series C financing round. The round included new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
Client Highlights
Wilson Sonsini Advises Upstart in Private Offering of $500 Million of Convertible Senior Notes
On November 15, 2024, Upstart Holdings, Inc. completed an offering of $500 million aggregate principal amount of 1.00% convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Upstart had granted to the initial purchasers to purchase up to an additional $75 million of notes.
Client Highlights
Firm Advises LuxWall on IP and Patent Strategy Matters Related to $51 Million Series B
On October 31, 2024, LuxWall, a leader in glass-based transparent insulation solutions to reduce energy consumption and carbon emissions from buildings, announced that it has closed a $51 million Series B funding round led by Climate Investment and Barclays Sustainable Impact Capital. New investors Carbon Equity and The Nature Conservancy participated in the round, alongside existing investors Breakthrough Energy Ventures, Prelude Ventures, 2150, Khosla Ventures, and Baruch Future Ventures. Wilson Sonsini Goodrich & Rosati advised LuxWall on IP and patent strategy in connection with the transaction.
The funding allows LuxWall to scale up production at its newly opened factory in Litchfield, Michigan, which received the support from Michigan Governor Gretchen Whitmer. It will also enable the construction and expansion of a second factory in Detroit, Michigan, as well as the growth of research and development at the R&D Center in Ypsilanti, Michigan.
The Wilson Sonsini team that advised LuxWall on the transaction includes Matt Bresnahan, Maysam Pessian, and Jane Yang.
For more information, please see LuxWall’s news release.
The funding allows LuxWall to scale up production at its newly opened factory in Litchfield, Michigan, which received the support from Michigan Governor Gretchen Whitmer. It will also enable the construction and expansion of a second factory in Detroit, Michigan, as well as the growth of research and development at the R&D Center in Ypsilanti, Michigan.
The Wilson Sonsini team that advised LuxWall on the transaction includes Matt Bresnahan, Maysam Pessian, and Jane Yang.
For more information, please see LuxWall’s news release.
Client Highlights
Wilson Sonsini Advises Stepful on $31.5 Million Series B Round
On November 13, 2024, Stepful, a company re-imagining healthcare training for allied health professional jobs, announced it successfully raised $31.5 million in Series B funding. The round was led by Oak HC/FT with participation from Y Combinator, Reach Capital, AlleyCorp, SemperVirens, Company Ventures, Green Sands, ECMC Education Impact Fund, Intermountain Ventures, and Cedar Pine. Wilson Sonsini Goodrich & Rosati represented Stepful in the transaction.
The latest issue of The Entrepreneurs Report compiles a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the third quarter of 2024, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. This edition also features a market perspective piece discussing AI start-ups and the venture capital ecosystem going into 2025.